Compare Heron Therapeutics Inc (HRTX) vs Msci Inc (MSCI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs Msci Inc — how do they compare? Heron Therapeutics Inc trades at $0.32 (market cap $63.41M), while Msci Inc trades at $562 (market cap $40.94B). The key difference: Msci Inc is far larger — about 645.6× Heron Therapeutics Inc's market cap, and Msci Inc pays a 1.46% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals.
| HRTX | MSCI | |
|---|---|---|
Market Cap | $63.41M | $40.94B |
Sector | Health | Financials |
52-Week High | $1.49 | $643.83 |
52-Week Low | $0.32 | $511.84 |
Enterprise Value | $161.31M | $47.10B |
Dividend Yield | — | 1.46% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Heron Therapeutics (HRTX) trades at $0.49, down 1.64% today, with a bearish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7M but missed earnings expectations with a $0.03 loss per share. Despite negative net income margins, HRTX maintains strong analyst support with 94.7% buy ratings. Recent news highlights patent litigation developments and quarterly earnings underperformance.
HRTX faces significant fundamental challenges with persistent losses and declining revenue projections, though analyst consensus remains overwhelmingly bullish. Investment opportunity exists if the company can achieve profitability and meet growth targets, but risks include ongoing operational losses, competitive pressures, and execution challenges in the biotechnology sector.
MSCI trades at $563.17, down 0.72% with bearish technical signals but strong fundamentals including 40.73% net margins and consistent earnings beats. The company shows robust revenue growth from $2.2B in 2022 to $3.13B in 2025, with positive cash flow trends. Recent acquisitions like First Street and partnerships with UBS enhance its private markets platform, supporting long-term growth in climate risk analytics and alternative investments.
Wall Street maintains strong bullish sentiment with 73% buy ratings and a $728.14 consensus target, implying 29% upside. Key risks include high debt levels at $4.51B and sensitivity to market cycles, but recurring revenue models and strategic expansions position MSCI for sustained outperformance despite near-term technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About Msci Inc
MSCI describes its mission as enabling investors to build better portfolios for a better world. MSCI's largest and most profitable segment is its index segment, where it provides benchmarking to asset managers and asset owners. In addition, it boasts over $1 trillion in ETF assets linked to MSCI indexes. The MSCI analytics segment provides portfolio management and risk management analytics software to asset managers and asset owners. MSCI's all other segment was broken out into ESG and climate and private assets segments in 2021. In ESG and climate, MSCI provides ESG data to the investment industry. In the private assets side, MSCI provides real restate reporting, market data, benchmarking, and analytics to investors and real estate managers.
Read more on MSCI →
